DOCSLIB.ORG

Acne Vulgaris Handout

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Acne Vulgaris Handout Acne vulgaris: A practical approach John C. Selby, M.D., Ph.D. Department of Dermatology University of Iowa Hospitals and Clinics Iowa City VA Health Care System Objectives (1) Understand the pathophysiology of acne vulgaris (2) Recognize common clinical variants of acne (3) Appreciate practical management principles based on clinical variant and disease severity Pathophysiology Acne vulgaris classically involves the face, upper back, and upper chest, all areas of the body where sebaceous glands are found in high density. Acne originates with a comedone, a non-inflammatory papule consisting of a follicular opening filled with keratin and excess sebum, commonly referred to as a “plugged pore”. Dysmaturation and abnormal cohesion of keratinocytes near the neck of the follicular opening create the “plug”. Excess sebum builds up behind the plug, due to androgen- mediated stimulation of the sebaceous gland. Cutibacterium acnes (formerly Propionibacterium acnes) in the resident flora of the follicle now trapped within this “plug” release lipases that breakdown sebum as well as trigger innate immune responses through activation of Toll-like receptors. If left unchecked, auto-amplification of the innate immune response leads to the development of an inflammatory papule or pustule. Ultimately, rupture of the follicle can lead to the formation of a deep inflammatory nodule. Depending on the magnitude of the inflammatory response, permanent scarring can occur, often accompanied by benign postinflammatory hyperpigmentation. Clinical Variants (a) Comedonal acne: patients who have open/closed comedones and only a few or no inflammatory lesions. (b) Inflammatory acne: patients who have predominantly inflammatory papules and pustules with some background open/closed comedones. (c) Nodulocystic acne: patients who have a preponderance of large deep inflammatory nodules together with background papules, pustules, and open/closed comedones. (d) Hormonal acne: women aged ~25-45 years who present with papules, pustules, and small nodules localized around the chin and jawline, often with background open/closed comedones. Differential diagnosis: • Drug-induced acne (anabolic steroids, lithium, EGFR-inhibitors, corticosteroids, isoniazid, phenytoin) • Rosacea • Periorificial dermatitis • Folliculitis • Pseudofolliculitis -1- Practical Management Note: Recommendations that follow assume that female patients are not pregnant nor are they attempting to conceive. Comedonal acne: 1. General skin care measures: (a) Wash face with a gentle skin cleanser once or twice daily. Over-the-counter Cetaphil Gentle Skin Cleanser is typically what is recommended in the Dermatology clinic (non-soap cleanser). (b) Check to ensure that all products applied to the skin, including make-up, moisturizers, and sunscreens, are labeled as oil-free and/or non-comedogenic. (c) Recommend avoidance of harsh “exfoliating” washes and scrub brushes and cleansers marketed for “oily skin.” In general, these products remove too much oil from the skin and lead to paradoxical stimulation of oil gland activity (seborrhea). 2. Topical retinoids: (a) Start all patients on tretinoin 0.025% cream [20g/month] applied daily at bedtime 3 nights per week for the first 2 weeks, then increase to nightly application as tolerated. -Nightly application is required because most retinoids are photolabile. (b) For patients who report intolerance of tretinoin, recommend use of over-the-counter adapalene 0.1% gel. (c) For patients who complain of oily skin, recommend starting with tretinoin 0.01% gel. (d) Retinoid tips: -Wash face, then wait ~20 minutes before applying a pea-sized amount of retinoid (tretinoin or adapalene) to the entire face. -Counsel patient that use of a topical retinoid will cause some degree of dryness and irritation, and this is a normal response. In the morning and/or at night, the patient may apply a topical over-the- counter non-comedogenic moisturizer to help offset this irritation (Cetaphil or CeraVe lotion). -Counsel patient that if they cannot tolerate nightly application, that is okay. However, if they can tolerate retinoid application 3 nights per week (scheduled), treatment will confer a clinical benefit. -Counsel patient that a topical retinoid is the most important medication for acne treatment because it is the only medication that treats comedone formation. However, the clinical response is slow and it can take 3-4 months of scheduled use to appreciate a clinical benefit. (d) At follow-up visits, if patient is tolerating nightly retinoid application, consider increasing the strength of the retinoid (using the same cream or gel vehicle). -For any new retinoid prescription, have the patient alternate application with their existing retinoid for 2 or 3 weeks before using the higher-strength retinoid on a nightly basis. -2- Inflammatory acne: 1. General skin care measures as per treatment of comedonal acne. 2. Topical retinoids as per treatment of comedonal acne. 3. Male patients: Identify and eliminate or minimize all prescription and over-the-counter testosterone-based treatments/supplements. 4. Anti-inflammatory medications: Mild disease (a) Start a benzoyl peroxide 2% to 5% (not 10%) wash (sometimes called a creamy wash) daily with each shower or bath (e.g., PanOxyl wash). Let the medicated wash sit on areas of skin affected with acne for several minutes prior to rinsing off. Use daily if tolerated. Otherwise, use only 2 or 3 days per week (scheduled). -Counsel the patient that benzoyl peroxide wash can bleach towels used for application of the wash, but it will not bleach clothes if thoroughly rinsed off the skin. -If inflammatory lesions are only present on the face, one can alternatively use a benzoyl peroxide 2% to 5% cream, gel, or lotion applied to active inflammatory lesions daily every morning. -Benzoyl peroxide products should not be used at the same time as topical retinoids because peroxides can degrade most retinoids and render them ineffective. Mild to moderate disease (a) Start a benzoyl peroxide product as noted for mild disease above. (b) Start clindamycin 1% gel or lotion applied to all areas of typical acne flare twice daily. -Okay to apply clindamycin together with a topical retinoid. (c) Counsel patient that it is important to maintain use of the benzoyl peroxide product while using topical clindamycin to help prevent the development of antibiotic resistance. Moderate to severe disease (a) Start a benzoyl peroxide product as noted for mild disease above. (b) Start doxycycline monohydrate (preferred) or doxycycline hyclate 100 mg oral twice daily for ~12 weeks (until next clinic follow-up visit). -Instruct the patient to take this medication with food to avoid causing dyspepsia. -Additionally, counsel the patient that this medication can also cause a photosensitivity reaction similar to a sunburn. Patients on doxycycline should wear a broad-spectrum sunscreen SPF>30 during periods of significant outdoor ultraviolet light exposure. -If patients complain of dyspepsia with doxycycline, recommend minocycline 100 mg twice daily. (c) Counsel patient that it is important to maintain use of the benzoyl peroxide product while using oral doxycycline or minocycline to help prevent the development of antibiotic resistance. Nodulocystic acne: 1. Refer to Dermatology for isotretinoin treatment (Accutane). 2. While patient is waiting for this appointment, initiate empiric treatment measures as described for inflammatory acne, moderate to severe disease. -3- Hormonal Acne: 1. General skin care measures as per treatment of comedonal acne. 2. Topical retinoids as per treatment of comedonal acne. 3. Initiate a benzoyl peroxide product as per treatment of inflammatory acne, mild disease. 4. After review of relevant risk factors, recommend combination oral contraceptive pills containing ethinyl estradiol and a third or fourth generation progestin like norgestimate or drospirenone (OrthoTri-Cyclen or Yaz; both are FDA-approved for acne vulgaris). 5. If acne remains sub-optimally controlled or if the patient is already on some other form of birth control (IUD, progestin monotherapy), start spironolactone 50 mg twice daily. -Counsel patient on possible side-effects including diuresis, menstrual irregularities, and breast tenderness. -In general monitoring of potassium levels in an otherwise healthy patient is not indicated. -Consider monitoring of potassium levels only in patients with significant cardiac disease, renal insufficiency, and/or or patients who are taking medications that can affect potassium levels (ACE inhibitors). -If spironolactone at a dose of 50 mg twice daily confers benefit but acne remains sub-optimally controlled, okay to increase dose to a maximum of 100 mg twice daily. After initiating the above measures, have the patient return to clinic in 3 or 4 months for re- evaluation. If acne remains sub-optimally controlled, advance therapy and/or consider placing a regular outpatient Dermatology Consult. Other clinical scenarios in which you might consider placing a regular outpatient Dermatology Consult: • Uncertain diagnosis of acne • Transgender patients • Pregnant females or patients attempting to conceive • Oncology patients undergoing systemic chemotherapy References [1] Wolff, K., and R.A. Johnson. Fitzpatrick’s Color Atlas and Synopsis of Clinical Dermatology, Sixth Edition. New York: McGraw-Hill, 2009. With excellent photographs and diagrams of various common skin diseases, accompanied by brief descriptions of the pathophysiology, laboratory
Load more

Recommended publications
  • Use of Undiluted Tea-Tree Oil As a Cosmetic
    Federal Institute for Risk Assessment (BfR) Use of undiluted tea-tree oil as a cosmetic Opinion of the Federal Insitute for Risk Assessment (BfR), 1th September 2003 Background Recently there has been an increasing amount of reports on contact-allergic eczema in con- junction with the use of tea-tree oil. Tea-tree oil is sold as a pure natural product, highly con- centrated and undiluted in cosmetics. Tea-tree oil is advertised as a universal remedy al- though there is no marketing authorisation as a pharmaceutical product. Concentrated tea-tree oil has been classified as harmful according to the self-classification of the International Fragrance Association (IFRA) and is labelled with R-phrases R 22 (harmful if swallowed) R 38 (irritating to skin) and R 65 (may cause lung damage if swallowed) as well as the symbol Xn (harmful) (IFRA Labelling Manual 1, 2001). These indications of health hazards are also part of the safety data sheets of raw material suppliers. At the 65th and 66th meetings of the Cosmetics Committee at the Federal Institute for Risk Assessment (BfR), health risks associated with the use of undiluted and highly concentrated tea-tree oil in cosmetic products were discussed extensively. Result Tea-tree oil is a mixture of various terpenes extracted from the Australian tea-tree. Undiluted tea-tree oil is a pure natural product. In the presence of atmospheric oxygen but also when exposed to light and higher temperatures, oxidation processes occur leading to the formation of peroxides, epoxides and endoperoxides which have a sensitising potency and may trigger allergic skin reactions.
    [Show full text]
  • Outpatient Acne Care Guideline
    Outpatient Acne Care Guideline Severity Mild Moderate Severe < 20 comedones or < 20-100 comedones or 15-50 > 5 cysts, >100 comedones, or inflammatory lesions inflammatory lesions >50 inflammatory lesions Initial Treatment Initial Treatment Initial Treatment Benzoyl Peroxide (BP) or Topical Combination Therapy Combination Therapy Topical Retinoid Retinoid + BP Oral antibiotic or OR + (Retinoid + Antibiotic) + BP Topical retinoid Topical Combination Therapy or + BP + Antibiotic Retinoid + (BP + Antibiotic) or OR BP Retinoid + BP Oral antibiotic + topical retinoid + +/- or BP Topical antibiotic Retinoid + Antibiotic + BP or Topical Dapsone IF Inadequate Response IF Inadequate Response IF Inadequate Consider dermatology Response referral Change topical retinoid Consider changing oral concentrations, type and/or antibiotic formulation AND or Add BP or retinoid, if not already Change topiocal combination Consider isotretinoin prescribed therapy Consider hormone therapy or and/or (females) Change topical retinoid Add or change oral antibiotic concentrations, type and/or or formulation Consider isotretinoin Additional Considerations or Consider hormone therapy (females) Change topical comination Previous treatment/history Side effects therapy Costs Psychosocial impact Vehicle selection Active scarring Ease of use Regimen complexity Approved Evidence Based Medicine Committee 1-18-17 Reassess the appropriateness of Care Guidelines as condition changes. This guideline is a tool to aid clinical decision making. It is not a standard of care. The physician should deviate from the guideline when clinical judgment so indicates. GOAL: Pediatricians should initiate treatment for cases of “Mild” to “Severe” acne (see algorithms attached). Pediatricians should also counsel patients in order to maximize adherence to acne treatment regimens: 1. Realistic expectations. Patients should be counseled that topical therapies typically take up to 6-8 weeks to start seeing results.
    [Show full text]
  • Formulary Drug Removals
    July 2018 Formulary Drug Removals Below is a list of medicines by drug class that have been removed from your plan’s formulary. If you continue using one of the drugs listed below and identified as a Formulary Drug Removal, you may be required to pay the full cost. If you are currently using one of the formulary drug removals, ask your doctor to choose one of the generic or brand formulary options listed below. Category Formulary Drug Formulary Options Drug Class Removals Allergies BECONASE AQ flunisolide spray, fluticasone spray, mometasone spray, triamcinolone spray, Nasal Steroids / Combinations OMNARIS DYMISTA QNASL ZETONNA Anticonvulsants ZONEGRAN carbamazepine, carbamazepine ext-rel, divalproex sodium, divalproex sodium ext-rel, gabapentin, lamotrigine, lamotrigine ext-rel, levetiracetam, levetiracetam ext-rel, oxcarbazepine, phenobarbital, phenytoin, phenytoin sodium extended, tiagabine, topiramate, valproic acid, zonisamide, FYCOMPA, OXTELLAR XR, TROKENDI XR, VIMPAT Anti-infectives, Antibacterials E.E.S. GRANULES erythromycins Erythromycins / Macrolides ERYPED Anti-infectives, Antibacterials MINOCIN minocycline Tetracyclines DORYX doxycycline hyclate DORYX MPC MONODOX Anti-infectives, Antibacterials MACRODANTIN nitrofurantoin Miscellaneous Anti-infectives, Antivirals VALCYTE valganciclovir Cytomegalovirus * Anti-infectives, Antivirals MAVYRET EPCLUSA (genotypes 1, 2, 3, 4, 5, 6), HARVONI (genotypes 1, 4, 5, 6), VOSEVI 1 Hepatitis C * DAKLINZA EPCLUSA (genotypes 1, 2, 3, 4, 5, 6), HARVONI (genotypes 1, 4, 5, 6) OLYSIO TECHNIVIE
    [Show full text]
  • Mechanisms of Action of Azelaic Acid 15% Gel: Assessing Its Broad Antioxidant and Comedolytic Effects Zoe Diana Draelos, MD
    CCOSMETIOSMETICC CCONSULTATIONONSULTATION Mechanisms of Action of Azelaic Acid 15% Gel: Assessing Its Broad Antioxidant and Comedolytic Effects Zoe Diana Draelos, MD wo small studies were undertaken to investi- Dermatologic medications can have a similar versatility gate the ability of azelaic acid (AzA) 15% gel of action. For example, tetracyclines are used for their T to function as a comedolytic and as a topical antibacterial and anti-inflammatory qualities to treat antioxidant. The first study compared AzA 15% gel with acne. Sodium sulfacetamide and sulfur combinations are benzoyl peroxide (BPO) 5% gel as a comedolytic. Ten used for antibacterial, antifungal, and anti-inflammatory participants were randomized to apply AzA 15% gel on purposes for acne, seborrheic dermatitis, and rosacea. one shoulder and BPO 5% gel on the other shoulder One could argue that versatile ingredients can often be twice daily for 4 weeks, with a nontreated site on the more valuable than those that deliver a single, albeit central back serving as the control in all participants. powerful, effect. Comedone counts were obtainedCOS at baseline and week DERM4 An alternate dermatologic prescription that has mul- by examination of cyanoacrylate biopsies taken from tiple mechanisms of action is AzA 15% gel. Also known each site. The AzA 15% gel and BPO 5% gel produced as nonanedioic acid, AzA is a saturated dicarboxylic acid substantial decreases in mean comedones (12 to 0.9 and found naturally in wheat, rye, and barley. It is also pro- 14.9 to 1.6, respectively) from baseline to week 4 as duced by the yeast Pityrosporum ovale, a natural compo- compared with controlsDo (14.6 to 10.9).
    [Show full text]
  • Comparing 2.5%, 5%, and 10% Benzoyl Peroxide on Inflammatory
    Pharmacology and Therapeutics Comparing 2.5%, 5%, and 10% Benzoyi Peroxide on Inflammatory Acne Vulgaris OTTO H. MILLS, JR., PH.D., ALBERT M. KLICMAN, M.D., PH.D., PETER POCHI, M.D., AND HARRIET COMITE, M.D. From the Departments of Dermatology, University of Subjects, Materials, and Methods Pennsy/vania School of Medicine, Philadelphia, Pennsylvania, and Boston University School of Medicine, Clinical Studies Boston, Massachusetts The same methods were used to conduct three double- blind studies. After giving informed consent, subjects with mild to moderately severe inflammatory acne vulgaris of the face (minimum of 10 inflammatory lesions) were assigned to one of the three treatment groups. A total of 153 subjects, 74 men and 79 women (average age of 20 years), participated ABSTRACT: A 2.5% formulation of benzoyi peroxide was in the three studies. In the first, 25 subjects used 2.5% ben- compared with its vehicle, and with a 5% and a 10% proprietary zoyi peroxide gel and 25, the gel vehicle for this formulation. benzoyi peroxide gel preparation in three double-blind studies In the second, 26 used the 2.5 gel and 27, a 5% gel. The involving 153 patients with mild to moderately severe acne third study consisted of 25 subjects who used the 2.5% gel vulgaris. The 2.5% benzoyi peroxide formulation was more and 25, a 10% benzoyi peroxide gel. The subjects received effective than its vehicle and equivalent to the 5% and 10% no medications for any reasor\s during \he 4-week period concentrations in reducing the number of inflammatory lesions prior to the start of the study.
    [Show full text]
  • Long-Term Use of Spironolactone for Acne in Women: a Case Series of 403 Patients
    Long-term use of spironolactone for acne in women: A case series of 403 patients Vaibhav Garg, BS,a JulianaK.Choi,MD,PhD,b William D. James, MD,b and John S. Barbieri, MD, MBAb Philadelphia, Pennsylvania Background: There are limited data regarding the long-term outcomes of spironolactone use for women with acne and its effect on truncal acne. Objective: To comprehensively describe outcomes of patients treated with spironolactone in routine clinical practice, including long-term outcomes. Methods: We performed a retrospective case series of 403 adult women treated for acne with spironolactone at an academic medical center between 2008 and 2019. Rates of objective, as assessed by Comprehensive Acne Severity Scale scores, and subjective acne clearance were evaluated, as well as rates of treatment discontinuation, dosage changes, and drug survival. Logistic regression was used to assess for association between incidence of menstrual adverse effects and combined oral contraceptive use. Results: As evaluated by Comprehensive Acne Severity Scale scores, at the first follow-up, 75.5%, 84.0%, and 80.2% of patients with available data had reduction or complete clearance of acne on the face, chest, and back, respectively. The mean drug survival was 470.7 days. Menstrual adverse effects were less common among those using combined oral contraception (odds ratio, 0.23; 95% confidence interval, 0.11-0.50). Limitations: This study was conducted at a single academic medical center. Conclusions: Spironolactone improves clinical outcomes and is well tolerated for many adult women with acne using it for an extended duration. ( J Am Acad Dermatol 2021;84:1348-55.) Key words: acne; acne vulgaris; birth control pill; combined oral contraceptive; comprehensive acne severity scale; oral antibiotics; outcomes; spironolactone.
    [Show full text]
  • Therapeutic Drug Class
    BUREAU FOR MEDICAL SERVICES WEST VIRGINIA MEDICAID EFFECTIVE PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA 04/01/11 This is not an all-inclusive list of available covered drugs and includes only Version 2011.9 managed categories. Refer to cover page for complete list of rules governing this PDL. • Prior authorization for a non-preferred agent in any category will be given only if there has been a trial of the preferred brand/generic equivalent or preferred formulation of the active ingredient, at a therapeutic dose, that resulted in a partial response with a documented intolerance. • Prior authorization of a non-preferred isomer, pro-drug, or metabolite will be considered with a trial of a preferred parent drug of the same chemical entity, at a therapeutic dose, that resulted in a partial response with documented intolerance or a previous trial and therapy failure, at a therapeutic dose, with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis. (The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.) • Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC drugs are not covered unless specified. • PA criteria for non-preferred agents apply in addition to general Drug Utilization Review policy that is in effect for the entire pharmacy program, including, but not limited to, appropriate dosing, duplication of therapy, etc. • The use of pharmaceutical samples will not be considered when evaluating the members’ medical condition or prior prescription history for drugs that require prior authorization.
    [Show full text]
  • Aetna Formulary Exclusions Drug List
    Covered and non-covered drugs Drugs not covered – and their covered alternatives 2020 Advanced Control Plan – Aetna Formulary Exclusions Drug List 05.03.525.1B (7/20) Below is a list of medications that will not be covered without a Key prior authorization for medical necessity. If you continue using one of these drugs without prior approval, you may be required UPPERCASE Brand-name medicine to pay the full cost. Ask your doctor to choose one of the generic lowercase italics Generic medicine or brand formulary options listed below. Preferred Options For Excluded Medications1 Excluded drug name(s) Preferred option(s) ABILIFY aripiprazole, clozapine, olanzapine, quetiapine, quetiapine ext-rel, risperidone, ziprasidone, VRAYLAR ABSORICA isotretinoin ACANYA adapalene, benzoyl peroxide, clindamycin gel (except NDC^ 68682046275), clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, EPIDUO, ONEXTON, TAZORAC ACIPHEX, esomeprazole, lansoprazole, omeprazole, pantoprazole, DEXILANT ACIPHEX SPRINKLE ACTICLATE doxycycline hyclate capsule, doxycycline hyclate tablet (except doxycycline hyclate tablet 50 mg [NDC^ 72143021160 only], 75 mg, 150 mg), minocycline, tetracycline ACTOS pioglitazone ACUVAIL bromfenac, diclofenac, ketorolac, PROLENSA acyclovir cream acyclovir (except acyclovir cream), valacyclovir ADCIRCA sildenafil, tadalafil ADZENYS XR-ODT amphetamine-dextroamphetamine mixed salts ext-rel†, dexmethylphenidate ext-rel, dextroamphetamine ext-rel, methylphenidate ext-rel†, MYDAYIS,
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • MINOCYCLINE for Acne
    This policy statement is approved by Halton, Knowsley, Liverpool, South Sefton, Southport and Formby, St Helens, Warrington, and Wirral CCGs Ha Kn Li SS SF SH Wa Wi MINOCYCLINE for acne The Pan Mersey Area Prescribing Committee does not recommend the prescribing of MINOCYCLINE for acne. BLACK The NHS England document ‘Items which should not routinely be prescribed in primary care: Guidance for CCGs’ contains the following advice.1 Recommendation Advise CCGs that prescribers in primary care should not initiate minocycline for any new patient with acne. Advice CCGs to support prescribers in de-prescribing minocycline in all patients with acne and, where appropriate, ensure the availability of relevant services to facilitate this change. Exceptions and further No routine exceptions have been identified. recommendations Category Products of low clinical effectiveness, where there is a lack of robust evidence of clinical effectiveness or there are significant safety concerns. Annual spend in Pan £13,796 Mersey area (Epact Jan. 2020) Background and Minocycline is a tetracycline antibiotic that can be used for many indications but is Rationale mainly used in primary care for acne. Minocycline is mainly used for acne however there are various safety risks associated with its use. NICE CKS advises Minocycline is not recommended for use in acne as it is associated with an increased risk of adverse effects such as drug induced lupus, skin pigmentation and hepatitis. A PrescQIPP CIC review found there is no evidence to support the use of one tetracycline over another in terms of efficacy for the treatment of acne vulgaris and alternative once daily products are available2.
    [Show full text]
  • Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services
    Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services Australian Statistics on Medicines 1997 i © Commonwealth of Australia 1998 ISBN 0 642 36772 8 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be repoduced by any process without written permission from AusInfo. Requests and enquiries concerning reproduction and rights should be directed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra, ACT 2601. Publication approval number 2446 ii FOREWORD The Australian Statistics on Medicines (ASM) is an annual publication produced by the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee. Comprehensive drug utilisation data are required for a number of purposes including pharmacosurveillance and the targeting and evaluation of quality use of medicines initiatives. It is also needed by regulatory and financing authorities and by the Pharmaceutical Industry. A major aim of the ASM has been to put comprehensive and valid statistics on the Australian use of medicines in the public domain to allow access by all interested parties. Publication of the Australian data facilitates international comparisons of drug utilisation profiles, and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes. The data available in the ASM represent estimates of the aggregate community use (non public hospital) of prescription medicines in Australia. In 1997 the estimated number of prescriptions dispensed through community pharmacies was 179 million prescriptions, a level of increase over 1996 of only 0.4% which was less than the increase in population (1.2%).
    [Show full text]
  • Benzoyl Peroxide Vs. Salicylic Acid WHAT to USE and WHEN
    benzoyl peroxide vs. salicylic acid WHAT TO USE AND WHEN BENZOYL PEROXIDE AND SALICYLIC ACID ARE THE TWO MAIN INGREDIENTS IN MOSI OVER-THE-COUNTER TOPICAL ACNE PRODUCTS. BUT HOW DO THEY WORK, HOW ARE qr' THEY DIFFERENT AND WHICH ONE IS RIGHT FOR YOU7 > salicylic acid PREVENTS CLOGGED PORES BY AIDING ExFoLImIoN Atne forms wheh skin ceUs inside the hair falltck clump together and phq up the fulUcle. Salicylic HOW TO USE acid help sped cot1 twrnovgr on the surfate and slow the shedding of cells inside the foliicte tcr I.i pkwnt the clogging that causes a pimple. 5~lieylicacid aLo breaks down whiteheads ad San Francisco dermatologist blackheads. Technicalty a beta hydraxy acid, salicylic acid exfoliates and reduces oiliness, acne and Kathy Fields. MD, recommends 4 the appeal-nee of fine lines. It Is availableover-thecaunter in concentrstiom of 0.5 ta 246. but those a leave-on product or gentle , with sensitive skin shwld start with a lcHnier contentratton before trying stronger prcrducts. scrub or wash that doesn't strip ' the skin of moisture. "The key is to find a product you like using so you stick with it." she says. This ingredient can be irritating to sensitive skin, especially when combined with benzoyl peroxide, sulfur or other acne treatments. Mild stinging upon application is common. Salicylic acid may cause increased sun sensitivity, so be sure to use sunscreen daily. Salicylic acid must be used con- tinuously for results. If you stop, your pores will get clogged once again and your acne will return. KINERASE CLEAR SKlX w6xLERAGNOSw MWiUo CUIIEtFflNG Salicylic acid does not have an BLtSHlSH OIssOlVER OVERNIM ACNE CtEAmml effect on the production of REPAIR LOTION This spot treatment contains In addition to salitylic acid, sebum Ithe skin's natural oil], salicylic acid and glycolic acid Fight acne and aging with one this daily cleanser contains tri- or P.
    [Show full text]